SI
BHVN

Sofinnova Investments’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Sofinnova Investments’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-124,952
Closed -$6.43M – 90
2019
Q1 		$6.43M Buy
124,952
+27,507
+28% +$1.19M 0.62% 32
2018
Q4 		$3.6M Sell
97,445
-35,621
-27% -$1.28M 0.45% 42
2018
Q3 		$5M Buy
+133,066
New +$4.89M 0.45% 38

Other funds holding BHVN

Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sofinnova Investments's BHVN Position: Q2 2019 in Review

Sofinnova Investments sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2019, closing a stake of 124,952 shares — an estimated $6.43M sold.

Sofinnova Investments first reported a position in BHVN in Q3 2018 and held it in 3 quarters. The position peaked at $6.43M in Q1 2019. 197 funds tracked by Wall St. Rank hold BHVN as of Q2 2019.

  • Sofinnova Investments reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2019 after selling out during the quarter.
  • Sofinnova Investments sold 124,952 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2019, an estimated $6.43M.
  • Sofinnova Investments first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 3 quarters.
  • Sofinnova Investments's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $6.43M in Q1 2019.
  • 197 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2019.

Based on Sofinnova Investments's 13F filing for Q2 2019, filed 13 Aug 2019.